

Anti-HPV16 E6+HPV18 E6 (Clone: C1P5)

Mouse monoclonal antibody
Reference: AP10510; AP10510C



1 of 2

INTENDED USE AND PRESENTATION:

For research use only.

AP10510, 7 ml. Prediluted antibodies in a synthetic organic linear polymer buffer solution (pH 7.4), with carrier protein and preservative for stabilisation "READY TO USE"

AP10510C, 1 ml. Concentrated antibodies with carrier protein and preservative for stabilisation.

SUMMARY, EXPLANATION AND LIMITATIONS:

Human papilloma viruses (HPVs) can be classified as either high risk or low risk according to their association with cancer. HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types. Approximately 90 % of cervical cancers contain HPV DNA of the high risk types. Mutational analysis have shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function. The specific interactions of the E6 and E7 proteins with p53 and pRB, respectively, correlate with HPV high and low risk classifications. The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro.

Immunohistochemistry (IHC) is a complex technique in which immunological and histological detection methods are combined. In general, the manipulation and processing of tissues before immunostaining, especially different types of tissue fixation and embedding, as well as the nature of the tissues themselves may cause inconsistent results (Nadji and Morales, 1983). Endogenous pseudoperoxidase and peroxidase activity or endogenous biotin and alkaline phosphatase activity can cause non-specific staining results depending on the detection system used. Tissues that contain Hepatitis B surface antigen (HBsAg) can produce false positives when using HRP detection systems (Omata et al, 1980). Insufficient contrast staining and/or improper mounting of the sample may influence the interpretation of results.

Isotype: IgG1

Immunogen: Gel-purified HPV-18 E6-beta galactosidase fusion protein.

Staining pattern: Nuclear.

The interpretation of the stain results is the full responsibility of the user. Any experimental result must be confirmed by a medically established diagnostic product or procedure.

Positive control: Tissue sample from cervical carcinoma.

External negative control: Tissue sample homologous to the test sample incubated with an antibody isotype not specific for HPV16 E6+HPV18 E6.

APPLICATIONS:

This antibody is designed for the specific localization of HPV16 E6+HPV18 E6 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.

PRODUCT COMPOSITION:

Mouse immunoglobulin IgG1, clone C1P5, obtained from cell culture supernatant. The preparation contains saline buffer, stabilising and carriers proteins, and sodium azide as a preservative.

METHODS AND PROCEDURE:

Principles of the procedure: The demonstrations of antigens by IHC is a sequential procedure with several steps involving first the application of a specific antibody for the antigen of interest (primary antibody), then a secondary antibody which joins to the first, an enzyme complex, and the addition of a chromogenic substrate. The sample is washed between each step. Enzymatic activation of the chromogenic substrate creates a visible product where the antigen is located. The results are interpreted using a light microscope. The primary antibody can be used both in manual IHC and with automated immunostainers.

Specimen: Paraffin-embedded tissue samples should be used. Western blot techniques are not recommended.

Staining procedure:

Antigen retrieval	HIER Citrate Buffer pH 6.5
Working dilution (only for concentrates)	1:50 – 1:500
Incubation	30 min; RT
Control Tissue	Cervical carcinoma

Amplification and development of the immunostaining:

follow standard procedure and the recommendations given by the manufacturer for the materials used. In the case of using automated immunostainers, use the specified buffers and materials for each instrument.

See our web site at www.gennova-europe.com for detailed protocols ancillary reagents and support products.

REQUIRED MATERIALS BUT NOT SUPPLIED:

All reagents, materials, and laboratory equipment for IHC procedures are not provided with this antibody. This includes adhesive slides and cover slips, positive and negative control tissues, Xylene or adequate substitute, ethanol, distilled H₂O, heat pretreatment equipment (pressure cooker, steamer, microwave), pipettes, Coplin jars, glass jars, moist chamber, histological baths, negative control reagents, counter-staining solution, mounting materials, and microscope. Buffered solutions for antigen retrieval, enzyme treatments, highly sensitive detection systems, and other auxiliary reagents are available from Gennova Scientific.

STORAGE AND STABILITY:

Store at 2-8 °C until the expiration date printed on product label. Do not use after the expiration date. If fresh solutions are required, these must be prepared immediately prior to use, and will be stable for at least one day at room temperature (20-25°C). Unused portion of antibody preparation should be discarded after one day. If the product is stored under different conditions from those stipulated in



Catalog number



Batch code



Research use only



Temperature limitation



Expiration date



Manufacturer



See instruction for use



Gennova Scientific, S.L.
C/ Johann Gutenberg, 4F. Pol. Ind.
El Cnamo I • 41300 San Jos
de La Rinconada • Sevilla, SPAIN
Telfono: +34 954 150767
Fax: +34 955 266494

info@gennovalab.com
www.gennova-europe.com

Anti-HPV16 E6+HPV18 E6 (Clone: C1P5)

Mouse monoclonal antibody
Reference: AP10510; AP10510C



2 of 2

these technical indications, the new conditions must be verified by the user.

Gennova Scientific guarantees that the product will maintain all of the described characteristics from the production date until the expiration date, as long as the product is stored and used as recommended. No other guarantees are provided. Under no circumstances is Gennova Scientific obliged to cover damages caused by use of this reagent.

TROUBLESHOOTING:

If unusual staining is observed or any other deviations from the expected results, please read these instructions carefully, along with the instructions from the detection system. If this does not solve the problem, please contact Gennova Scientific's technical support department or your local distributor.

PRECAUTIONS:

Use only by qualified personnel.

Use proper protective equipment in order to avoid contact with reagents and samples in the eyes, skin, and mucosal tissues. In case of contact with sensitive areas, immediately flush the affected area with water. Avoid microbial contamination of the reagent, as this may produce nonspecific staining results. This antibody contains sodium azide (NaN₃), used as a stabilising agent, which is not considered to be a hazardous material in the concentration used. Concentration of sodium azide in drainage pipes made of lead or copper can cause the formation of highly explosive metallic azides. In order to avoid this, sodium azide must be disposed of along with a large volume of running water. Material safety data sheet (MSDS) for pure sodium azide is available upon request.

PERFORMANCE CHARACTERISTICS:

Gennova Scientific has performed studies to evaluate the functioning of these antibodies for use with standard detection systems, concluding that the product is both specific and sensitive for the antigen of interest.

BIBLIOGRAPHY:

Wang, W. et al. 2010. Selective targeting of HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo. *Cancer Lett.* 291: 67-75.
Tsai, YY. et al. 2009. HPV infection and p53 inactivation in pterygium. *Mol. Vis.* 15: 1092-1097.
Sima, N. et al. 2008. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. *Apoptosis.* 13: 273-281.
Shuyama, K. et al. 2007. Human papillomavirus in high- and low-risk areas of oesophageal squamous cell carcinoma in China. *Br J Cancer.* 96: 1554-1559.
Sima, N. et al. 2007. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. *Gynecol Oncol.* 106: 299-304.
Nadji M, Morales AR. Immunoperoxidase, part 1: the techniques and its pitfall. *Lab Med* 1983; 14:767-770.
Omata M, Liew CT, Ashcavai M, Peters RI. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen. A possible source of error in immunohistochemistry. *Am J Clin Pathol.* May, 1980;73(5):626-632.

F01IT04_V1R1111_AP10510_English



Catalog number



Batch code



Research use only



Temperature limitation



Expiration date



Manufacturer



See instruction for use



Gennova Scientific, S.L.
C/ Johann Gutenberg, 4F. Pol. Ind.
El Canamo I • 41300 San Jose
de La Rinconada • Sevilla, SPAIN
Telefono: +34 954 150767
Fax: +34 955 266494

info@gennovalab.com
www.gennova-europe.com